<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741219</url>
  </required_header>
  <id_info>
    <org_study_id>OBGynFudanU</org_study_id>
    <nct_id>NCT02741219</nct_id>
  </id_info>
  <brief_title>A Multicenter Study: Dexmedetomidine Combined With Sufentanil for Patient Controlled Intravenous Analgesia After Caesarean Section</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Obstetrics &amp; Gynecology Hospital of Fudan University</source>
  <brief_summary>
    <textblock>
      The purpose of this multicenter study is to evaluate the effectiveness and safety of
      dexmedetomidine combined with sufentanil for patient-controlled analgesia after caesarean
      section
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sufentanil consumption</measure>
    <time_frame>During 24h after surgery</time_frame>
    <description>The total consumption of sufentanil during 24h after surgery are recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pain score</measure>
    <time_frame>At 0, 4, 8 and 24 h after surgery</time_frame>
    <description>Pain scores at rest and movement are evaluated with a visual analogue scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Ramsay sedation score (RSS)</measure>
    <time_frame>At 4, 8 and 24 h after surgery</time_frame>
    <description>Sedation intensity measured with RSS is recorded at the 4, 8 and 24 h after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic blood pressure</measure>
    <time_frame>At 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery.</time_frame>
    <description>Systolic blood pressure is recorded at 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Press times of analgesic pump</measure>
    <time_frame>During 24h after surgery</time_frame>
    <description>The total press times and invalid press times are recorded during 24h after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate (HR)</measure>
    <time_frame>At 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery</time_frame>
    <description>HR is recorded at 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in saturation of blood oxygen (SpO2)</measure>
    <time_frame>At 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery</time_frame>
    <description>SpO2 is recorded at 0 min, 5 min, 10 min, 30 min after intervention during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic blood pressure</measure>
    <time_frame>At 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery</time_frame>
    <description>Diastolic blood pressure is recorded at 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean arterial blood</measure>
    <time_frame>At 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery</time_frame>
    <description>Mean arterial blood pressure is recorded at 0 min, 5 min, 10 min, 30 min after intervention during surgery and at 8h,24 h after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Control Group receives normal saline bolus after delivery</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery</description>
    <arm_group_label>Dex Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>sufentanil PCA after surgery</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil and dexmedetomidine</intervention_name>
    <description>sufentanil combined with dexmedetomidine PCA after surgery</description>
    <arm_group_label>Dex Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parturients undergoing elective caesarean delivery under spinal anaesthesia

          2. American Society of Anesthesiologists class I and II parturients aged 18-45 years,
             with term singleton pregnancies

          3. Parturients with the ability to understand verbal and written mandarin

          4. Parturients who want to use PCA intravenous analgesia and can use the pump correctly

          5. Parturients whose written informed consent have been obtained

        Exclusion Criteria:

          1. A history of allergy to dexmedetomidine or other study drugs

          2. A long use history of opioid analgesic, NSAIDs, tranquilliser use

          3. Psychiatric disorders

          4. A history of neuromuscular and endocrine disease or allergic disease

          5. A history of lower abdominal surgery

          6. Preoperative heart rate (HR) less than 50 bpm, SBP less than 100 mmHg or cardiac
             conduction or rhythm abnormalities

          7. spinal anaesthesia was unsuccessful or an epidural catheter had to be used to achieve
             adequate anaesthesia

          8. A second operation is required during the study.

          9. Participating other study during the latest three months

         10. Body mass index more than 30 kg/m2

         11. Difficult airway ( Mallampati score more than 3 and anatomic deformity )

         12. Not suitable for participation estimated by investigation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NIE Yuyan, MD</last_name>
    <phone>8613564761627</phone>
    <email>fan0116@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HUANG Shaoqiang, MD</last_name>
    <phone>8613918210787</phone>
    <email>timrobbins@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NIE Yuyan, MD</last_name>
      <phone>8613564761627</phone>
      <email>fan0116@163.com</email>
    </contact>
    <contact_backup>
      <last_name>HUANG Shaoqiang, MD</last_name>
      <phone>8613918210787</phone>
      <email>timrobbins71@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Nie Yuyan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

